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2-(a-Hydroxybenzyl)-benzimidazole (HBB)  1 and guanidine are highly selective 
and potent inhibitors  of picornavirus  multiplication  in cell culture  (1,  2),  but 
little is known about their protective effects in virus-infected animals.  Animal 
experiments with HBB or its chemical derivatives and guanidine so far yielded 
at most marginal  protective effects, in most cases a  striking antiviral  activity 
was  not  observed  (3-7).  The  discrepancy  between the  results  in  cell  culture 
systems and animals  was explained on the basis of rapid emergence of drug- 
resistant mutants. In fact, drug-resistant mutants can easily be obtained in cell 
culture  (7-9),  and  isolation  of  drug-resistant  mutants  from  virus-infected, 
treated animals has been reported (4, 7). 
In view of the high antiviral potency of HBB and guanidine in cell culture we 
made another  attempt in animals  under hopefully optimum conditions.  First, 
newborn  mice  infected  with  echo  virus  type  9  were  used.  The  relationship 
between virus multiplication and occurrence of paralysis in young mice has been 
studied extensively (10); an outstanding feature is the development of resistance 
to the virus with increasing age of the animals.  Second, HBB in water-soluble 
form and as D-isomer, the compound of higher antiviral activity (11), was used. 
Third,  HBB and guanidine were injected in combination: both compounds act 
synergistically  (9,  12)  and  exhibit  only  limited  cross-resistance  vs.  mutants 
resistant to one compound (9). 
In this paper, the successful treatment of echo virus type 9 and Coxsackie A 9 
virus disease in newborn mice by HBB and guanidine,  as well as some decisive 
parameters of treatment,  will be described. 
Materials  and Methods 
Viruses.  Echo virus type 9, A. Barty (10), and Coxsackie virus A type 9, Woods (8), have been 
described before.  They were propagated  in primary cultures of trypsinized kidney tissue from 
rhesus or African green monkeys (8). 
Cell Cultures.  Monkey kidney cells were purchased in suspension from Flow  Laboratories 
(Flow  Laboratories  Inc.,  Rockville,  Md.)  and seeded into  tubes or  plastic  Petri  dishes in our 
*  Aided  by  grants  from  the  Verein der  Foerderer  der  Universitaet  zu  Koeln,  the  Pesch-Stiftung, 
and the Minister  fuer  Wissenschaft  und Forschung des Landes Nordrhein-Westfalen. 
Abbreviations used in this  paper: GMK, African  green monkey kidney tissue;  HBB, 2-(a- 
hydroxybenzyl)-benzimidazole;  MEM, minimum essential  medium; PD5o,  50% paralyzing  doses; 
TCIDso, 50% tissue  culture  infective  doses. 
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laboratory. The growth medium consisted of Eagie's minimum essential medium (MEM) (13) with 
added fetal calf serum to a concentration of 2-5%. The serum had been inactivated at 56°C for 30 
rain. 
For virus titrations and determination of drug sensitivity of virus sometimes a continuous cell 
line derived from African green monkey kidney tissue (GMK) was used, kindly supplied by Dr. H. 
Lennartz, Hamburg, FRG. It was maintained in serial passages by growth in MEM with 10% fetal 
calf serum. 
Infectivity Titrations.  Virus  titrations in tube  cultures  were  essentially  done  as  described 
before (8). The maintenance medium for primary cultures was MEM, for GMK cell cultures MEM 
with 2% fetal calf serum.  Concentration of infective virus was expressed in terms of 50% tissue 
culture infective doses (TCIDso)  per 0.1 ml. 
Plaque assays were performed on primary monkey kidney or GMK cell monolayers. After 1-h 
adsorption at room temperature the inoculum was removed and the plates overlaid with 5 ml of a 
mixture consisting of equal volumes of 1.8% agar and two times concentrated reinforced Eagle's 
MEM (14) with 2 or 5% fetal calf serum. Infectivity titers of unadapted echo 9 or Coxsackie A  9 
virus in GMK cultures were usually 2-3 times lower than in primary cultures, but all titrations 
from the same experiment were clone simultaneously in the same Cell system. 
Drug Sensitivity Tests.  They were done in tube cultures or by plaque technique as described 
previously (8,  15). 
Neutralization Tests.  The technique followed a  standard tube neutralization test which has 
been described in detail previously (16). 
Compounds.  HBB was used throughout in its D-(-) optical isomeric form (11) as hydrochlo- 
ride salt. It was kindly synthesized for us by Farbwerke Hoechst AG, Hoechst, FRG. Guanidine, 
as hydrochloride salt, was purchased from E. Merck, Darmstadt, FRG. 
Mice.  NMRI  mice  were  either purchased  from  an  animal  supply  house  or  reared  in  the 
Institute's animal quarters. Mice were infected, less than 24-h old, by subcutaneous inoculation of 
virus dilutions in 0.02 ml vol. The mice were observed for 21 days at least once a day, and clinical 
manifestations as well as deaths were recorded. Concentration of virus in mice was expressed in 
terms of 50% paralyzing doses (PDs0) per 0.02 ml. 
Standard treatment of mice consisted of subcutaneous inoculations of 0.02 ml vol of saline (0.9% 
sodium hydrochloride in pyrogen-free water) with or without compounds as indicated, beginning 
at  the  time  of  virus  inoculation  and  extending  for  usually  10  days.  The  inoculations  were 
administered into the region of the forearm two times daily, with the right and left side alternat- 
ing.  The standard concentrations of compounds were  10 mM  HBB plus  100 mM guanidine for 
combined treatment, for HBB alone 10 mM HBB, and for guanidine alone 100 mM guanidine. 
As indicated in the text, isolation of more mouse-virulent echo virus 9 was achieved by passage 
in Swiss albino mice. These were kindly provided by ASTA-Werke AG, Brackwede, FRG. 
Results 
Protective Action  of Combined  Treatment against Echo  Virus  Type  9  Dis- 
ease.  Litters of  newborn mice were infected with 1-5 PDso of cell culture-grown 
echo virus 9,  corresponding to about 2  ×  106 plaque-forming units (PFU) per 
mouse. Starting at time of virus inoculation, they were simultaneously treated 
in 0.02 ml doses two times daily for 8-10 days by subcutaneous inoculations of 10 
mM HBB plus 100 mM guanidine, by 10 mM HBB alone, or 100 mM guanidine 
alone, respectively. Assuming an initial body weight of a mouse of  about 1 g and 
uniform distribution of compound, a final concentration of 200 ~M HBB and 2 
mM guanidine might be achieved in the animal after one inoculation. These are 
well tolerated and highly virus-inhibitory concentrations of the compounds in 
cell culture (8). 
The results of 11 experiments extending over half a year are summarized in 
Table  I.  In  the  virus  control  group  more  than  90%  of the  animals became 
paralyzed and 85% of the paralyzed mice died. In some experiments, the mice of HANS  J.  EGGERS  1369 
TABLE I 
Effect of HBB/Guanidine Treatment on Echo 9 Virus Disease in Newborn Mice 
Virus control  10 mM HBB* + 100  10 mM HBB  100 mM guanidine 
mM guanidine 
94/1025  4/111  20/20  15/15 
(80/94 died)  (1/4 died)  (all died)  (all died) 
* 0.02 ml of drugs inoculated subcutaneously two times daily for 8-10 days, beginning at 
time of virus inoculation. 
* Number of mice paralyzed over total number of mice. 
the control group were kept untreated; in most cases they were inoculated two 
times daily with saline, but this apparently did not influence the outcome of  the 
experiment.  The protective effect of the combined treatment with HBB plus 
guanidine is obvious: out of 111 mice only 4 became ill, and 3 of  these 4 mice had 
only a  slight muscular weakness of short  duration.  Even the  fourth mouse 
probably would have survived, but, unfortunately, was eaten by its mother. On 
the other hand, HBB or guanidine treatment alone were ineffective. 
That the protective effect of combined treatment is not limited to relatively 
low doses of virus is demonstrated in Table II. More virulent variants of virus 
were prepared by repeated virus passages in Swiss albino mice (10). It can be 
seen  that  combined treatment  with  HBB  plus  guanidine,  according to  the 
schedule outlined above, protects completely against more than 103 PDs0. HBB 
alone, even in 20 mM concentration, had no demonstrable protective effect. The 
clinical success of treatment can be correlated with inhibition of virus multipli- 
cation as seen in the following experiment. 
Inhibition of Virus Multiplication in Treated Mice.  Groups of newborn mice 
were infected with five PD50 of echo virus 9 and treated two times daily for 91/2 
days with either saline, 10 mM HBB plus 100 mM guanidine, 10 mM HBB alone, 
or 100 mM guanidine alone, respectively. At indicated times after virus inocula- 
tion, two mice of each group were collected and frozen at -20°C. Subsequently, 
of each mouse a  20% suspension in MEM was prepared and the virus content 
determined in  rhesus  monkey kidney cell  cultures.  In Fig.  1 the  geometric 
means of the titrations are presented. Clearly, a  significant inhibition of echo 
virus 9 multiplication was found in the group treated with HBB plus guanidine, 
though ultimately also in this group the virus titers reached high levels. How- 
ever,  as known from previous studies (10), this delay in virus multiplication 
is quite sufficient to prevent echo virus 9 disease in mice. On the nature of the 
"breakthrough" virus, we shall comment below. It should be stressed that not in 
all experiments a late virus multiplication occurred in the treated group (see, 
e.g., Fig. 6). It is also obvious from this experiment that treatment with HBB or 
guanidine alone had no effect on virus multiplication which corresponds to the 
lack of clinical improvement under these two treatments. 
Modifications of the Standard Schedule of Combined Treatment.  Since echo 
virus 9 multiplication does reach its maximum in newborn mice around 3-4 days 
(10) (see also Figs. 1 and 6), an attempt was made to abbreviate the combined 
treatment with HBB plus guanidine. Groups of mice, after inoculation of five 
PDso of echo virus 9, were subjected to standard treatment, which, however, was 
cut short to only 5 or 3 days, respectively (Table III). Not only 5 days but even 3 8- 
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TABLE  II 
Effect of HBB/Guanidine Treatment of Newborn Mice Inoculated with 
Higher Doses of Echo 9 Virus 
10mMHBB  + 
Experiment  PDs0 inoculated  Saline*  100mMguan-  20mMHBB 
idine 
7-10-74  103. 5  8/8~  0/4  - 
1-02-75  103.  2  8/8  0/6  - 
14-02-75  102. 5  6/6  0/7  8/8 
* 0.02  ml of  saline  or  drugs inoculated subcutaneously two times daily  for  81/2-101/2 
days, beginning at time of  virus inoculation. 
Number of  mice paralyzed over total  number of  mice. 
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Multiplication of echo virus 9 in newborn mice, treated two times daily for 91/2 
days with  either  saline,  10  mM  HBB plus I00 mM  guanidine, 10  mM  HBB alone,  or 100 mM 
guanidine alone, respectively. HANS  J.  EGGER8  1371 
TABLE IH 
Abridged Treatment of Echo 9 Virus-Infected Newborn Mice 
with HBB /Guanidine 
Virus control 
10 mM HBB  +  100 mM guanidine* 
For 3 days  For 5 days 
5/5*  0/3  0/11 
(no survivors) 
* 0.02 ml inoculated subcutaneously two times daily, beginning at time 
of virus inoculation. 
Number of mice paralyzed over total number of mice. 
days of treatment beginning with virus inoculation were sufficient for preven- 
tion of paralysis. In a  complementary experiment of similar design (five PDs0 
per mouse), combined treatment was delayed for 24 or 48 h  after virus inocula- 
tion,  respectively (Table  IV).  Postponement of treatment for even 48  h  was 
sufficient for protection of the animals. 
The dose of drugs administered appeared to be critical (Table V).  When only 
half of  the standard dose of  combined treatment was inoculated (5 mM HBB plus 
50 mM guanidine), no longer complete, though still significant, protection of 
mice inoculated with five PDso of echo virus 9 was achieved. Quarter doses (2.5 
mM HBB plus 25 mM gnanidine) were ineffective. Results comparable to those 
with half of the standard dose were obtained when the standard dose of HBB 
plus guanidine was administered only once daily instead of  twice per day (Table 
VI). 
Toxicity of Treatment.  Toxicity experiments were carried out by treating 
marked mice from single litters with saline or test substances in saline, respec- 
tively. Treatment was begun in animals less than 24-h old and maintained for 
10-11 days. Inoculations were administered two times daily, 0.02 ml per mouse 
per injection. Weights of all mice were taken daily. Under these conditions 20 
mM HBB  or  100  mM guanidine, respectively, never proved toxic. In several 
experiments 200 mM guanidine led to cyanosis in the mice, and these animals 
frequently died or were eaten by their mothers. 
20 mM HBB plus 200 mM guanidine injected together sometimes also proved 
toxic, in other experiments it was tolerated and no difference in weight gain to 
the saline control was detected (Fig. 2).  Whether HBB acts somewhat alleviat- 
ing on gnanidine toxicity cannot be decided. 
Drug Sensitivity of Virus Recovered from Treated Mice.  HBB or guanidine 
treatment alone of echo virus 9-infected mice is ineffective (Table I),  and no 
inhibition of virus multiplication in the animals thus treated can be demon- 
strated  (Fig.  1).  Since  drug-resistant mutants can be  easily obtained in cell 
culture, it has been argued that development of drug resistance might be the 
cause of clinical ineffectiveness. Therefore, echo virus 9 recovered at various 
times after infection from HBB- or guanidine-treated mice with clinical disease 
was tested for HBB or guanidine sensitivity and compared with material iso- 
lated from  corresponding animals of the  saline  group  as  well  as  the  virus 
originally inoculated. 
Drug  sensitivity was  measured  as  described  before  (8)  by  recording  the 1372  HBB  AND  GUANIDINE  TREATMENT  OF  ENTEROVIRUS-INFECTED  MICE 
TABLE  IV 
Delayed Treatment of Echo 9 Virus-Infected Newborn Mice with 
HBB  /Guanidine 
Virus control 
10  mM  HBB  + 100 mM  guanidine* 
At time of  24 h post-  48 h  post- 
virus  inoculation  inoculation 
6/6*  0/3  0/9  0/9 
(no survivors) 
* 0.02  ml  inoculated  subcutaneously  two  times  daily  until  101/2  days  postinocu- 
lation  of  virus. 
* Number of  mice paralyzed over  total  number of  mice. 
TABLE  V 
Effect of Varying Doses of  HBB/Guanidine on Echo 9 Virus Disease in Newborn Mice 
10 mM HBB  5 mM HBB +  50 mM  2.5 mM HBB +  25 mM 
Saline*  +  100 mM 
guanidine  guanidine  guanidine 
8/8*  0/4  2/5  10/10 
(6 survivors)  (all survived)  (no survivors) 
* 0.02  ml of  saline  or  drugs  inoculated  subcutaneously  two  times  daily  for  10x/2  days,  beginning  at 
time of  virus  inoculation. 
* Number of  mice paralyzed over  total  number of  mice. 
TABLE  VI 
Effect of Combined Treatment Given Only One Time Per Day 
Saline* 
10 mM HBB +  100 mM guanidine 
Two times daily  One time daily 
9/9*  0/9  4/9 
(no  survivors)  (7  survivors) 
* 0.02 ml of saline or drugs inoculated subcutaneously for 11 days, 
beginning  at  time of  virus  inoculation. 
* Number of  mice paralyzed over  total  number of  mice. 
development of viral cytopathic effects in tube cultures under varying concen- 
trations of compound as compared to untreated cultures. In another series of 
tests reduction of the number and size of plaques with various concentrations of 
compound in the overlay was measured. 
Fig. 3 gives a typical example of HBB sensitivity of echo virus 9 recovered on 
days 7 to 11 after virus inoculation from mice kept either untreated or treated 2 
times daily for 91/2 days with 10 mM HBB. No significant difference between 
virus recovered from mice of either the untreated or HBB group is apparent. 
Fig. 4 represents corresponding results from guanidine-treated mice. Results of 
this nature were obtained in large series of  experiments using either the tube or 
plaque  reduction method.  Similar results  were  also  obtained with  HBB-  or 
guanidine-treated mice infected with Coxsackie A 9 virus (see below). Thus, we 
conclude that development of drug-resistant variants cannot be a  significant 
factor for the  failure of treatment when HBB  or  gnanidine is  administered HANS  J.  EGGERS  1373 
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FIG. 2.  Weight gain of  newborn mice inoculated subcutaneously two times daily  for 11 
days with 20 mM  HBB plus 200 mM  guanidine as compared to saline  controls. 
alone. So far, we recorded only one instance when a  sample of Coxsackie A 9 
virus from a  mouse successfully treated with HBB plus guanidine was signifi- 
cantly more  resistant to  HBB  and guanidine, respectively,  than the  parent 
virus.  This, however, might be an epiphenomenon, since samples from other 
mice of the same group exhibited an HBB and guanidine sensitivity like that of 
the virus inoculum. 
Treatment  of Mice Infected  with Drug-resistant  Virus.  Though the  data 
presented so far favor the conclusion that the protective effects of treatment are 
due to the virus-selective activity of the compounds, stronger evidence on this 
point appeared desirable. We, therefore, tried to prepare an echo virus 9 mutant 
doubly resistant to HBB and guanidine, respectively. Although it is very easy to 
isolate drug-resistant mutants in cell culture,  these  mutants usually are  no 
longer mouse pathogenic. After many futile attempts, we succeeded in obtaining 
a  mutant highly resistant to HBB and guanidine as compared to the parent 
virus  (Fig.  5),  exhibiting about one  PDso when given undiluted (about  106"7 
TCIDso per 0.1 ml). 
With this virus preparation standard growth curves in four litters of mice 
were performed, two of which were treated 2 times daily with saline, the other 
two with 10 mM HBB plus 100 mM guanidine. For comparison, drug-sensitive 
parent virus was used in an experiment of the same design. As can be seen in 
Fig. 6, multiplication of drug-sensitive virus was strongly inhibited in the drug- 
treated group and, as expected, residual drug-treated mice not taken for virus 
titration remained well in contrast to saline-treated mice. On the other hand, 1374  HBB  AND  GUANIDINE  TREATMENT  OF  ENTEROVIRUS-INFECTED  MICE 
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HBB sensitivity of echo virus 9 recovered  from m~ce kept untreated  or treated with 
the  multiplication  of the  HBB-guanidine-resistant  echo  virus  9  mutant  was 
quite similar in both the saline- and the drug-treated group. Clinically, two out 
of five mice in the saline group, not taken for virus titration, exhibited paresis; 
in the  drug-treated group two out of four remaining mice  were  paretic.  The 
results of this experiment  leave  hardly any doubt that the protection of mice 
treated with HBB and guanidine is due to the specific virus-inhibitory activity of 
these compounds. HANS  J.  EGGER8 
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Protective Action  of Treatment against  Coxsackie  A  9  Virus Disease.  As 
indicated in Table VII, the protective effect of combined treatment with HBB 
plus  guanidine  is  not  limited  to  echo  virus  9-infected  mice,  but can  also  be 
demonstrated in Coxsackie A 9 virus-infected animals. Furthermore, in the case 
of Coxsackie A  9 virus infection,  treatment with  10 mM HBB  alone is clearly 
effective.  On the other hand, guanidine treatment alone is without demonstra- 
ble effect.  The results on Coxsackie A 9 virus multiplication in treated animals 
are in line with the clinical findings (Fig.  7): no apparent virus multiplication 
until at least day 4 after infection in the HBB-guanidine-treated  group, and a 
significant delay in the HBB-treated  group as compared to the saline group, a 
delay quite  sufficient for protection of the animals.  In guanidine-treated  ani- 
mals, no inhibition of virus multiplication as compared to controls was demon- 
strated (figure not shown). 
The  fact  that  HBB  treatment  alone protected  Coxsackie  A  9-  but not echo 
virus  9-infected  mice,  could  be  thought  of  as  being  due  to  a  higher  HBB 
sensitivity  of the  Coxsackie  A  9  as compared  to the  echo virus  9,  though in 
previous studies such a  difference has not been noted (8,  17).  Upon careful re- 1376  HBB  AND  GUANIDINE  TREATMENT  OF  ENTEROVIRUS-INFECTED  MICE 
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examination in simultaneous tests  (Fig.  8),  no difference in HBB sensitivity 
between Coxsackie A 9 and echo virus 9 was detected. We conclude that factors 
other than HBB sensitivity are responsible for the effectiveness of HBB treat- 
ment in Coxsackie A 9 virus-infected mice. 
Immunity of Echo Virus 9-infected, HBB-Guanidine-treated Mice.  Though 
immunity of previously infected HBB-guanidine-treated mice for obvious rea- 
sons cannot be measured directly in challenge studies, two observations strongly 
suggest that, in fact, a solid immunity does develop. Firstly, sera taken from a 
number  of echo  virus  9-infected,  HBB-guanidine-treated mice at the  age  of 
about 2 mo, all contained echo virus 9 neutralizing antibodies, though, on the 
average,  in somewhat lower titers than those found in untreated or  saline- 
treated animals.  Secondly, children born to and fed by mothers which 2  mo 
previously had been protected by HBB-guanidine treatment from echo virus 9 
disease, were solidly immune to homologous virus infection administered within 
24 h  after birth, but succumbed to Coxsackie A 9 virus challenge. 
Discussion 
Combined treatment of echo virus 9-infected, newborn mice with HBB plus 
guanidine protects them from paralysis and death, even when more than 1,000 
PD5o of virus are inoculated. HBB or guanidine alone are ineffective. Treatment HANS  J.  EGGERS  1377 
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was usually begun at the time of virus inoculation and extended through  10 
days, but it may be cut short to 3 days of treatment beginning at time of virus 
inoculation. Treatment may also be delayed for 48 h after virus inoculation and 
still be effective. 
Coxsackie A 9 virus-infected mice are not only protected from paralysis and 
death by combined treatment,  but also by treatment with HBB alone.  Guani- 
dine alone, however, does not protect. 
That success of  treatment is due to the well-studied antiviral activities of  HBB 
and guanidine  is strongly suggested by the following finding.  There  exists a 
good correlation between protective activity of the compounds and inhibition of 1378  HBB  AND  GUANIDINE  TREATMENT  OF  ENTEROVIRUS-INFECTED  MICE 
TABLE VII 
Effect of HBB/Guanidine Treatment on Coxsackie A  Type 9 Virus Disease in Newborn 
Mice 
10  mM 
Experi-  PDs0 in-  HBB  + 
ment  ocu-  Saline*  100 rnM  10 mM  HBB  100  mM  guanidine 
fated  guani- 
dine 
20-6-74  4.6  9/9~  0/9 
(no survivors) 
5-7-74  4.6  8/8  0/5  6/8 
(5  survivors)  (all recovered 
after slight 
weakness) 
6-7-74  4.6  7/7  -  0/5  3/3 
(no survivors)  (no survivors) 
*  0.02  ml of  saline  or  drugs  inoculated  subcutaneously  two times  daily  for  10  days,  beginning  at 
time  of  virus  inoculation. 
*  Number of  mice  paralyzed  over  total  number of  mice. 
virus multiplication in the mice. In particular, HBB-guanidine-resistant  mu- 
tants prepared in cell  culture multiply unaffected  in treated mice, and those 
mice do not respond to treatment. 
A  most critical  factor for success of treatment in echo virus 9-infected mice 
appears to be a pharmacological one, viz,  to reach an adequate concentration of 
drugs in the target organ, the skeleton muscle. If  our standard dose of  combined 
treatment is only halved, either by lowering the concentration  of drugs or by 
reducing  the  number  of injections, still a  significant protective effect is 
achieved, but it is borderline, and quarter doses are ineffective (Tables V  and 
VI). On the other hand, due to toxicity  the concentration  of guanidine can at 
most be increased by a factor  of  two. 
Considering the above dose-effect  relationships and the very strong synergis- 
tic effects  of HBB  plus guanidine (9, 12),  the failure of treatment with either 
drug alone in the case of echo virus 9 infection appears reasonably explained. 
Whatever the  pharmacological basis,  in  the  broadest sense, may be: at  the site  of 
action in the muscle not too effective  concentrations  of either drug are being 
reached.  More detailed  pharmacokinetic  studies are under way to shed more 
light on this point, in particular, whether the conditions in the muscle are 
comparable to those of cell  culture systems. 
That the situation may be a more complex one is already suggested by the 
present study: though in cell  culture Coxsackie A 9  virus is  not more sensitive  to 
HBB  than echo virus 9 (Fig.  8), its multiplication in the muscle is inhibited by 
administration to  the mouse of  10 mM  HBB  alone, which latter  concentration is 
also clinically  effective,  whereas in the case of  echo virus 9 even 20 mM  HBB  is 
ineffective.  It may be speculated that in the mouse muscle the sites  of  attack of 
Coxsackie A 9 and echo virus 9, respectively, are not the same. This problem is 
being investigated at present in our laboratory. 
Failure of  HBB  or guanidine treatment alone, at  least  in  our case,  appears not C~ 
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to be due to the rapid emergence of drug-resistant virus mutants as anticipated 
first by analogy with cell culture studies and by the reports that after treatment 
of poliovirus-infectod monkeys with HBB or  guanidine, HBB-  or  guanidine- 
resistant mutants of  poliovirus were readily isolated (4, 7). In extensive series of 
experiments we were unable to isolate HBB- or guanidine-resistant mutants 
from treated animals. Thus,  failure of treatment with each compound alone 
appears not to be a  result of development of drug-resistant mutants, and the 
protective activity of combined treatment in all likelihood is a  consequence of 
the synergism between HBB and guanidine, and not that of the limited cross- 
resistance  between  HBB-  or  guanidine-resistant  variants,  respectively. 
O'Sullivan et al. in a study with the 1-propyl derivative of HBB in Coxsackie A 9 
virus-infected mice also found no evidence for formation of resistant virus (5). It 
is not yet clear why guanidine- or HBB-resistant mutants of poliovirus are so 
readily isolated from guanidine- or HBB-treated monkeys. 
Hollinshead and Smith (3) were the first to report therapeutic effects of HBB. 
They fed the free base of HBB in the diet to mice, infected with poliovirus 2 
(MEF1),  and recorded reduction of death  (8/11 in the control vs.  1/12 in the 1380  HBB  AND  GUANIDINE  TREATMENT  OF  ENTEROVIRUS-INFECTED  MICE 
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treated  group).  It  should  be  emphasized  that  poliovirus  is  relatively  HBB- 
insensitive  (8),  and  in  another  series  of experiments  HBB  did  not  protect 
poliovirus-infected mice (4). In the above mentioned study with 1-propyl-HBB in 
Coxsackie A 9 virus-infected mice (5), the authors gave the free base suspended 
in  corn  oil  intraperitoneally  in  doses up  to  1.6  mg per  mouse  per  day  (our 
standard dose 0.09 mg per mouse per day). With 3 days of treatment (usually 0.8 
mg per  mouse per day, distributed  in two doses),  beginning  at time  of virus 
inoculation, they achieved a delay in occurrence of death (with 20 LDso of virus) 
or a slight protection of 46% survival vs. 25% survival in the control (two LD50 of 
virus). Any possible advantages of the procedures of treatment with the benzim- 
idazole derivatives alone in O'Sullivan's et al. and our study cannot be evaluated 
properly yet, since the systems may not be comparable.  A  controlled series of 
experiments is under way. It should be stated, however, that in cell culture we 
did  not  find  1-propyl-HBB superior  in  its  virus  selectivity  to  DL-HBB,  the 
racemic form (Eggers and Tamm, 1963, unpublished results), not to speak of the 
D-isomer of HBB. 
Combined treatment of Coxsackie B virus-infected mice (types 2 and 4) so far 
gave only marginal beneficial effects (unpublished). In further experiments, the 
pharmacology  of the  substances  in  the  organism  will be considered  in  great 
detail; at present it appears to us a key problem in the pursuit of our studies. 
Summary 
Echo  virus  9-  or  Coxsackie A  9-infected  newborn  mice  are  protected from 
paralysis  and  death  by combined  treatment  with  nontoxic  concentrations  of 
HBB plus guanidine.  HBB alone also protects Coxsackie A 9, but not echo virus 
9-infected animals, whereas guanidine alone is ineffective in either case. Protec- 
tion is due to inhibition of virus multiplication via the antiviral activity of these HANS  J.  EGGEP~  1381 
selective inhibitors.  Treatment  must  be begun  at the  latest  48  h  after virus 
inoculation.  3  days of treatment  are  sufficient  if started  at the  time  of virus 
inoculation.  Failure  of protection  after treatment with one compound alone is 
not due to rapid development of drug-resistant virus mutants. Infected, success- 
fully treated mice may develop a  solid immunity. 
I wish to thank Mrs. Erika Dudas and Mrs. Brigida  Kraemer for diligent  expert  technical 
assistance  and the great  patience  with our mice and myself,  while working at unusual hours 
during work- and holidays. 
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